Day: March 16, 2023

PITTSBURGH, March 16, 2023 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the year ended December 31, 2022. Full Year Highlights:Revenues of $205.6 million, increased 38.8% year-over-year Net Income of $35.2 million, increased 877.3% year-over-year Non-GAAP Adjusted EBITDA of $70.5 million, increased 152.4% year-over-year RNG production of 5.5 million MMBtu, decreased 2.9% year-over-yearMontauk’s full year revenue reflects an increase in pricing of both gas commodity and the average realized price of D3 Renewable Identification Numbers (“RINs”) sold. The increase in price offset a decrease in RNG volumes produced and the...

Southlake, Texas, March 16, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023. Key Milestones during Fiscal Q3 2023 and to date:Engaged in multi-year collaboration with Rutgers University to develop AI-based ECG algorithms Further international patents granted, bringing total patent portfolio to 40 (nine U.S., 31 internationally) Balance sheet strengthened through the amendment and exercise of pre-IPO bridge warrants, $15 million equity facility and extension...

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and Combination Treatment $20 Million of Gross Proceeds from Capital Raise in February 2023 Adds to Cash Position of $17.1 Million as of December 31, 2022; Additional $13 Million Milestone Payment Expected in 1H 2023 NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2022 and provided a business update. “Broad success defines the past year, with positive efficacy signals...

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2022 and early 2023 Highlights:Significant progress was made on the conduct of the ASPIRE global clinical trial studying ivospemin (SBP-101) in combination with gemcitabine and nab-paclitaxel in the first-line treatment of metastatic pancreatic ductal adenocarcinoma:Initiated ASPIRE trial in January 2022 Received approval from the Australian Human Research Ethics Committee (HREC) to expand the ASPIRE global clinical...

First Half 2023 Highlighted by 58% Total Revenue and 40% MRR Increases Year-Over-Year Product Upgrades and Cost Structure Optimization Drive Path to Profitability PERTH, Australia, March 16, 2023 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in local search engine marketing, today reported financial results for the 2023 fiscal first half ended December 31, 2022. Recent Operational HighlightsAnnounced an updated profitability timeline, highlighted by significant reductions in operational expenditures and the launch of Locafy Brand Boost and Keystone products. Locafy management now projects that the Company will reach profitability during the 2023 fiscal fourth quarter. Named as a finalist in the 2022-2023 Cloud Awards in...

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received $25 million equity investment from Pfizer, and entered into clinical development collaboration with Pfizer for a potential Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Cash and investments of $228.2 million expected to fund operating plan into first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022. “We...

Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential clinical data this year Goal to submit two INDs this year for SC262 and SG299 Targeting multiple additional INDs in 2024 Q4 2022 cash position of $434.0 million Current cash position enables for runway into 2025 SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022. “2022 began our transformation from a research focused organization to a clinical-stage company, setting the stage for important clinical data in 2023 and 2024 to...

Company to host conference call March 16, 2023, at 4:30 PM EDT SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2022 financial results and provided an update on the cytisinicline development program. Recent HighlightsPresented additional analyses from the Phase 3 ORCA-2 trial at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting Announced accomplishment of key milestones, including last subject dosing and last subject visit, in the Phase 2 ORCA-V1 trial evaluating cytisinicline for e-cigarette cessation Completed dosing of...

–Record Full Year Gross Margin with Continued Margin Expansion– CHINO, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 HighlightsNet sales of $92.7 million, up 1.5 percent from the prior-year quarter. Gross profit of $29.7 million, negatively impacted by an out-of-period inventory write-off of $1.7 million, up 4.8 percent from the prior-year quarter. Gross margin of 32.0 percent, an improvement of 100 basis points over the prior-year quarter. Net income of $4.5 million (net income margin of 4.9 percent), versus $6.0 million (net income margin of 6.5 percent) in the prior-year...

– Robust Pipeline in Life Sciences Sector Positions Business for Growth in 2023 – – Significantly Reduced SG&A in The Quarter and Year – – 58% Reduction in Net Loss and Slight Adjusted EBITDA Loss in The Fourth Quarter Reflect Operating Leverage In Business Model As Company Scales – FREDERICK, Md., March 16, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the fourth quarter and year ended December 31, 2022. TOMI Chief Executive Officer, Dr. Halden Shane, stated, “2022 delivered continued growth in our revenue and sales pipeline as well as improved year over year financial operating...